1[1]Oseroff A, Krishnamurtic C, Hassett A, et al. Plas-minogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med, 1989; 113:88
2[2]Kern MJ, Henry RH, Lembo N, et al. Effects of pulsed external augmentation of diastolic pressure on coronary and systemic hemodynamic in patients with coronary artery disease. Am Heart J, 1985; 110:727
3[3]Pizzo SV, Petruska DB, Daman KA, et al. Releasable vascular plasminogen activator and thrombotic strokes.Am J Med, 1985; 79:407
4[4]Gracia- Frade LJ, Alvarrez JJ, Rago I, et al. Fibrinolytic parameters and lipoprotein (a) levels in plasma of patients with coronary artery disease. Thromb Res,1991; 63: 407
5[5]Landin K, Tengborn L, Smith U, et al. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1 ) in hypertension are related to metabolic risk factors for cardiovascular disease. J Inter Med, 1990; 227: 273
6[6]Brow BG, Christian A, Gallery BA, et al. Incomplefelysis of the thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantivate angiographic observations. Circulation, 1986; 73:653
7[7]Ettenger MM, Maccarthy EP, Glas- Gree WP, et al.Abnormalities of fibrinolysis in essential hypertension. J Hypertens, 1984; 2:175 .
8[8]Hamsten A, Wiman B, Farie U, et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of acute myocardial infarction. N Engl J Med, 1985; 313:1557
9[9]Juhan- Vague I, Alessic MC, Joly P, et al. Plasma plasminogen activator inhibitor in angina pectoris: influence of plasma insulin and acute phase response. Arteriosclerosis, 1989; 9:362
